After TherapeuticsMD reported that the top two TX-001 doses were statistically significant and clinically meaningful in the company's Phase 3 trial, Stifel analyst Annabel Samimy noted that the company's estradiol+progesterone product, if approved, would not only be the first E+P therapy to come to market but also that it demonstrates differentiation on multiple levels. The analyst, who sees a directly addressable market of $3.5B-$4.5B if approved, raised his price target on TherapeuticsMD shares to $17 from $14 and keeps a Buy rating on the stock, which is up about 30% to $8.01 in pre-market trading.